Immuno-Positron Emission Tomography with Zirconium-89-Labeled Monoclonal Antibodies in Oncology: What Can We Learn from Initial Clinical Trials?

Selection of the right drug for the right patient is a promising approach to increase clinical benefit of targeted therapy with monoclonal antibodies (mAbs). Assessment of in vivo biodistribution and tumor targeting of mAbs to predict toxicity and efficacy is expected to guide individualized treatme...

Descripción completa

Detalles Bibliográficos
Autores principales: Jauw, Yvonne W. S., Menke-van der Houven van Oordt, C. Willemien, Hoekstra, Otto S., Hendrikse, N. Harry, Vugts, Danielle J., Zijlstra, Josée M., Huisman, Marc C., van Dongen, Guus A. M. S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2016
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4877495/
https://www.ncbi.nlm.nih.gov/pubmed/27252651
http://dx.doi.org/10.3389/fphar.2016.00131

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4877495/
https://www.ncbi.nlm.nih.gov/pubmed/27252651
http://dx.doi.org/10.3389/fphar.2016.00131

Ejemplares similares